Wassim Kassouf Selected Research

Carcinoma in Situ

1/2024	Carcinoma In Situ (CIS): Is There a Difference in Efficacy between Various BCG Strains? A Comprehensive Review of the Literature.
1/2019	ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.
6/2017	Pathology review impacts clinical management of patients with T1-T2 bladder cancer.
1/2017	Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction.
10/2014	Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer.
11/2013	Regional differences in practice patterns and outcomes in patients treated with radical cystectomy in a universal healthcare system.
7/2012	Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy.
8/2011	Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients.
1/2011	Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery.
5/2010	Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wassim Kassouf Research Topics

Disease

120	Urinary Bladder Neoplasms (Bladder Cancer) 02/2024 - 12/2004
88	Neoplasms (Cancer) 12/2023 - 05/2003
84	Carcinoma (Carcinomatosis) 01/2023 - 06/2006
17	Prostatic Neoplasms (Prostate Cancer) 01/2023 - 05/2003
14	Non-Muscle Invasive Bladder Neoplasms 01/2024 - 12/2009
14	Neoplasm Metastasis (Metastasis) 11/2015 - 02/2004
12	Renal Cell Carcinoma (Grawitz Tumor) 01/2023 - 05/2007
11	Carcinoma in Situ 01/2024 - 06/2006
10	Margins of Excision 01/2023 - 01/2009
5	Disease Progression 12/2023 - 05/2007
4	Hernia (Hernias) 10/2022 - 08/2005
4	Hydronephrosis 01/2021 - 05/2011
4	Lymphatic Metastasis 01/2013 - 02/2004
3	Obesity 01/2023 - 02/2013
3	Pathologic Constriction (Stenosis) 10/2022 - 01/2010
3	Adenocarcinoma 01/2020 - 03/2014
3	Carcinogenesis 11/2015 - 04/2009
2	Urinary Tract Infections (Urinary Tract Infection) 01/2023 - 09/2010
2	Infections 01/2023 - 01/2010
2	Hypertension (High Blood Pressure) 01/2022 - 08/2019
2	Ileus 02/2021 - 12/2013
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021 - 01/2020
2	Kidney Neoplasms (Kidney Cancer) 06/2019 - 06/2018
2	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 04/2012 - 01/2007
2	Extranodal Extension 03/2012 - 10/2006
2	Necrosis 11/2010 - 04/2010
2	Hematuria 04/2009 - 06/2008
2	Transitional Cell Carcinoma 08/2007 - 03/2006
1	Weight Loss (Weight Reduction) 01/2023
1	Surgical Wound Infection 01/2023
1	Urologic Neoplasms (Urological Cancer) 01/2023
1	Urogenital Neoplasms 01/2023
1	Tertiary Lymphoid Structures 01/2023
1	Ureteral Obstruction 10/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	Sarcopenia 01/2022
1	Hypertriglyceridemia 01/2022
1	Neuroendocrine Carcinoma 01/2021

Drug/Important Bio-Agent (IBA)

12	Biomarkers (Surrogate Marker)IBA 12/2023 - 06/2008
9	Cisplatin (Platino)FDA LinkGeneric 02/2024 - 06/2009
5	B7-H1 AntigenIBA 12/2023 - 08/2020
5	Immune Checkpoint InhibitorsIBA 12/2023 - 01/2020
5	Gemcitabine FDA Link 11/2022 - 10/2006
5	ErbB Receptors (EGF Receptor)IBA 02/2011 - 11/2005
4	Indicators and Reagents (Reagents)IBA 01/2023 - 04/2010
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2006
4	Gefitinib (Iressa)FDA Link 01/2013 - 11/2005
3	atezolizumabIBA 12/2023 - 01/2021
3	HMGB1 Protein (HMG1)IBA 01/2021 - 03/2016
3	Prostate-Specific Antigen (Semenogelase)IBA 08/2019 - 05/2003
3	Everolimus FDA Link 04/2017 - 12/2009
3	PPAR gammaIBA 01/2013 - 01/2006
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2008 - 02/2004
2	AntibodiesIBA 12/2023 - 02/2011
2	Testosterone (Sustanon)FDA Link 01/2022 - 08/2018
2	AndrogensIBA 01/2022 - 05/2003
2	Docetaxel (Taxotere)FDA Link 03/2020 - 08/2006
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2018 - 02/2015
2	Vinblastine (Vinblastine Sulfate)FDA Link 01/2018 - 02/2015
2	Methotrexate (Mexate)FDA LinkGeneric 01/2018 - 02/2015
2	Mitomycin (Mitomycin-C)FDA LinkGeneric 08/2014 - 09/2010
2	TOR Serine-Threonine KinasesIBA 09/2013 - 12/2009
2	Tumor Biomarkers (Tumor Markers)IBA 11/2010 - 04/2007
2	nuclear matrix protein 22IBA 12/2009 - 06/2008
2	Tyrosine Kinase InhibitorsIBA 08/2009 - 11/2005
2	LigandsIBA 04/2009 - 05/2005
1	Phenobarbital (Luminal)FDA Link 11/2023
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 07/2023
1	Prednisone (Sone)FDA LinkGeneric 07/2023
1	Metformin (Glucophage)FDA LinkGeneric 07/2023
1	Carboplatin (JM8)FDA LinkGeneric 11/2022
1	HDL CholesterolIBA 01/2022
1	Hemoglobins (Hemoglobin)IBA 01/2022
1	NivolumabIBA 12/2021
1	5-alpha Reductase InhibitorsIBA 01/2021
1	2-methylcyclopentadienyl manganese tricarbonyl (MMT)IBA 01/2021
1	TEMPOIBA 10/2020
1	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 08/2020

Therapy/Procedure

115	Cystectomy 02/2024 - 03/2006
64	Therapeutics 02/2024 - 05/2003
40	Nephroureterectomy 08/2020 - 02/2009
32	Drug Therapy (Chemotherapy) 02/2024 - 10/2006
31	Neoadjuvant Therapy 02/2024 - 07/2007
27	Lymph Node Excision (Lymph Node Dissection) 01/2021 - 01/2007
25	Adjuvant Chemotherapy 01/2020 - 01/2008
12	Radiotherapy 12/2023 - 03/2012
9	Immunotherapy 01/2024 - 12/2004
9	Nephrectomy 06/2019 - 05/2007
6	Prostatectomy (Retropubic Prostatectomy) 06/2022 - 07/2007
4	Castration 01/2022 - 07/2013
4	Urinary Diversion (Ileal Conduit) 11/2019 - 01/2010
3	Preoperative Exercise 01/2023 - 11/2014
3	Transurethral Resection of Bladder 01/2022 - 06/2017
2	Aftercare (After-Treatment) 01/2020 - 08/2018
1	Antibiotic Prophylaxis 01/2023
1	Stents 01/2023
1	Patient Readmission 01/2023
1	Immunomodulation 05/2021
1	Activities of Daily Living (ADL) 01/2021
1	Length of Stay 08/2020